CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects

Bibliography

• Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011;10:446-56
   PubMed Web of Science ®Google Scholar
• Chaudhry AS, Urban TJ, Lamba JK, et al. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther 2010;332:599-611
   PubMed Web of Science ®Google Scholar
• Fields MC, Labovitz DL, French JA. Hospital-onset seizures: an inpatient study. JAMA Neurol 2013;70:360-4
   Google Scholar
• Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults:expert opinion, 2005. Epilepsy Behav 2005;7(Suppl 1):S1-64
   PubMedGoogle Scholar
• Malerba A, Ciampa C, De Fazio S, et al. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res 2010;91:273-82
   PubMed Web of Science ®Google Scholar
• Wheless JW, Clarke DF, Arzimanoglou A, et al. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9:353-412
   PubMed Web of Science ®Google Scholar
• Yu PM, Zhu GX, Ding D, et al. Treatment of epilepsy in adults: expert opinion in China. Epilepsy & Behav 2012;23:36-40
   PubMed Web of Science ®Google Scholar
• Eadie MJ. The Treatment of Epilepsy. In: . PE. Shorvon SEngel J, editors. Phenytoin. In: Wiley, editor. Oxford 2015; In press
   Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63
   PubMed Web of Science ®Google Scholar
• Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-69
   PubMed Web of Science ®Google Scholar
• Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther 2014;96:542-8
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-76
   PubMed Web of Science ®Google Scholar
• Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014;312:525-34
   PubMed Web of Science ®Google Scholar
• Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24:1401-3
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58
   PubMed Web of Science ®Google Scholar
• Glazko AJ, Chang T, Baukema J, et al. Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration. Clin Pharmacol Ther 1969;10:498-504
   PubMed Web of Science ®Google Scholar
• Mamiya K, Ieiri I, Shimamoto J, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998;39:1317-23
   PubMed Web of Science ®Google Scholar
• Thorn CF, Whirl-Carrillo M, Leeder JS, et al. PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics 2012;22:466-70
   PubMed Web of Science ®Google Scholar
• Browne TR LBILR, Mattson RH, Meldrum Bs and Perucca E. Phenytoin and other hydantoins. Chemistry and biotransformation. In: Antiepileptic Drugs. 5th Edition. Williams and Wilkins; Lippincott, Philadelphia: 2002. p. 565-80
   Google Scholar
• Buehler BA, Delimont D, van Waes M, et al. Prenatal prediction of risk of the fetal hydantoin syndrome. New Engl J Med 1990;322:1567-72
   PubMed Web of Science ®Google Scholar
• Finnell RH, Bennett GD, Mather GG, et al. Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. Reprod Toxicol 1999;13:85-91
   PubMed Web of Science ®Google Scholar
• Micali G, Linthicum K, Han N, et al. Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy 1999;19:223-7
   PubMed Web of Science ®Google Scholar
• Santos NA, Medina WS, Martins NM, et al. Involvement of oxidative stress in the hepatotoxicity induced by aromatic antiepileptic drugs. Toxicol in vitro 2008;22:1820-4
   PubMed Web of Science ®Google Scholar
• Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48:1223-44
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I BM, Levy RH. Phenytoin and other hydantoins. Interactions with other drugs. In: Levy RH, Mattson RH, Meldrum Bs, Perucca E, editors. Antiepileptic Drugs. 5th Edition. Lippincott Williams & Wilkins; Philadelphia: 2002. p. 581-90
   Google Scholar
• Nomenclature CCa. Available from: http://www.cypalleles.ki.se/cyp2c9.htm [Cited 11 February 2015]
   Google Scholar
• Romkes M, Faletto MB, Blaisdell JA, et al. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991;30:3247-55
   PubMed Web of Science ®Google Scholar
• Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63
   PubMedGoogle Scholar
• Rettie AE, Haining RL, Bajpai M, et al. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 1999;35:253-5
   PubMed Web of Science ®Google Scholar
• Soga Y, Nishimura F, Ohtsuka Y, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 2004;74:827-34
   PubMed Web of Science ®Google Scholar
• Wang B, Wang J, Huang SQ, et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 2009;10:781-834
   PubMed Web of Science ®Google Scholar
• Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997;62:287-92
   PubMed Web of Science ®Google Scholar
• Hung CC, Lin CJ, Chen CC, et al. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004;26:534-40
   PubMed Web of Science ®Google Scholar
• Ninomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000;22:230-2
   PubMed Web of Science ®Google Scholar
• Kutt H, Wolk M, Scherman R, et al. Insufficient paraphydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964;14:542-8
   PubMed Web of Science ®Google Scholar
• Taguchi M, Hongou K, Yagi S, et al. Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab Pharmacokinet 2005;20:107-12
   PubMedGoogle Scholar
• Aynacioglu ASBJ, Bauer S, Sachse C, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999;48:409-15
   PubMed Web of Science ®Google Scholar
• Rosemary J, Surendiran A, Rajan S, et al. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res 2006;123:665-70
   PubMed Web of Science ®Google Scholar
• Caraco Y, Muszkat M, Wood AJ. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 2001;11:587-96
   PubMedGoogle Scholar
• Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005;15:779-86
   PubMed Web of Science ®Google Scholar
• Babu SP, Ramesh V, Samidorai A, et al. Cytochrome P450 2C9 gene polymorphism in phenytoin induced gingival enlargement: a case report. J Pharm Bioallied Sci 2013;5:237-9
   PubMedGoogle Scholar
• Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001;70:391-4
   PubMed Web of Science ®Google Scholar
• Citerio G, Nobili A, Airoldi L, et al. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology 2003;60:1395-6
   PubMed Web of Science ®Google Scholar
• Dorado P, Lopez-Torres E, Penas-Lledo EM, et al. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J 2013;13:359-61
   PubMed Web of Science ®Google Scholar
• Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001;11:803-8
   PubMedGoogle Scholar
• McCluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit Care 2009;10:222-4
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Narayan SK, Chanolean S, et al. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India. Neurol India 2007;55:408-9
   PubMed Web of Science ®Google Scholar
• Depondt C, Godard P, Espel RS, et al. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011;18:1159-64
   PubMed Web of Science ®Google Scholar
• Hennessy S, Leonard CE, Freeman CP, et al. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol 2009;49:1483-7
   PubMed Web of Science ®Google Scholar
• Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010;66:689-96
   PubMed Web of Science ®Google Scholar
• Lee AY, Kim MJ, Chey WY, et al. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004;60:155-9
   PubMed Web of Science ®Google Scholar
• Phabphal K, Geater A, Limapichart K, et al. Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients. Seizure 2013;22:103-8
   PubMed Web of Science ®Google Scholar
• Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci 2005;102:5507-12
   PubMed Web of Science ®Google Scholar
• Thakkar AN, Bendkhale SR, Taur SR, et al. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients. Neurol India 2012;60:577-80
   PubMed Web of Science ®Google Scholar
• Twardowschy CA, Werneck LC, Scola RH, et al. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy. Seizure 2013;22:194-7
   PubMed Web of Science ®Google Scholar
• van der Weide J, Steijns LS, van Weelden MJ, et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001;11:287-91
   PubMedGoogle Scholar
• Yamamoto Y, Takahashi Y, Imai K, et al. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes. Ther Drug Monit 2015;37:229-35
   PubMed Web of Science ®Google Scholar
• Bruni J. Phenytoin and other hydantoins. In: Levy RHMR, Meldrum RS, Perucca E, editors. Adverse effects. 5th edition. Williams & Wilkins, Lippincott; 2002
   Google Scholar
• Lee SK, Mori S, Kim DJ, et al. Diffusion tensor MRI and fiber tractography of cerebellar atrophy in phenytoin users. Epilepsia 2003;44:1536-40
   PubMed Web of Science ®Google Scholar
• Mavroudis IA, Manani MG, Petrides F, et al. Dendritic, axonal, and spinal pathology of the Purkinje cells and the neurons of the dentate nucleus after long-term phenytoin administration: a case report. J Child Neurol 2013;28:1299-304
   PubMed Web of Science ®Google Scholar
• De Marcos FA, Ghizoni E, Kobayashi E, et al. Cerebellar volume and long-term use of phenytoin. Seizure 2003;12:312-15
   PubMed Web of Science ®Google Scholar
• Masur H, Fahrendorf G, Oberwittler C, et al. Cerebellar atrophy following acute intoxication with phenytoin. Neurology 1990;40:1800-1
   PubMed Web of Science ®Google Scholar
• Kuruvilla T, Bharucha NE. Cerebellar atrophy after acute phenytoin intoxication. Epilepsia 1997;38:500-2
   PubMed Web of Science ®Google Scholar
• Alioglu Z, Sari A, Velioglu SK, et al. Cerebellar atrophy following acute phenytoin intoxication. J Neuroradiol 2000;27:52-5
   PubMed Web of Science ®Google Scholar
• McCormack M, Urban TJ, Shianna KV, et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics 2012;13:399-405
   PubMed Web of Science ®Google Scholar
• Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-10
   PubMedGoogle Scholar
• Loscher W, Klotz U, Zimprich F, et al. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50:1-23
   PubMed Web of Science ®Google Scholar
• Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008;71:1527-34
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Hellerbrand C, Nies AT, et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 2011;3:82
   PubMed Web of Science ®Google Scholar
• Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91
   PubMed Web of Science ®Google Scholar
• Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia 2006;47:318-22
   PubMed Web of Science ®Google Scholar
• Wilson JT, Hojer B, Tomson G, et al. High incidence of a concentration-dependent skin reaction in children treated with phenytoin. Br Med J 1978;1:1583-6
   PubMed Web of Science ®Google Scholar
• Elazzazy S, Abu Hassan T, El Seid A, et al. Toxic epidermal necrolysis associated with antiepileptic drugs and cranial radiation therapy. Case Rep Oncol Med 2013;2013:415031
   Google Scholar
• Cheung YK, Cheng SH, Chan EJ, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013;54:1307-14
   PubMed Web of Science ®Google Scholar